Georgetown Univ — research payments reported

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$78,093	16
2024	Research	$34,121	4
2023	Research	$35,445	3
2022	Research	$316,723	24
2021	Research	$117,351	25
2020	Research	$34,336	14
2019	Research	$1,585,257	22

Breakdown

Who paid Research payments · program years 2019–2025

AstraZeneca Pharmaceuticals LP $1,758,393 57 payments
Acerta Pharma LLC $185,985 11 payments
Janssen Research & Development, LLC $112,214 20 payments
AstraZeneca UK Limited $82,297 6 payments
Alexion Pharmaceuticals, Inc. $46,151 3 payments
Novo Nordisk AS $16,286 11 payments

Studies the money was for Research payments · program years 2019–2025

A Phase I II trial of Dosatinib and AZD9291 in patients with advanced nonsmall cell lung cancer with EGFR mutation $1,327,778 1 payment
A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP-196 in Combination with Obinutuzumab, and ACP-196 Monotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia $164,457 3 payments
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK) $78,093 16 payments
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients with Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation $68,649 6 payments
Phase III Open Label Study of MEDI 4736 With or Without Tremelimumab Versus Standard of Care SOC in Recurrent Metastatic Head and Neck Cancer $61,297 2 payments
This is a randomized open label multi center global Phase III study to assess the efficacy and safety of durvalumab plus tremelimumab combination therapy and durvalumab monotherapy versus sorafenib in the treatment of patients with no prior systemic therapy for unresectable HCC $53,045 6 payments
A Phase III, Randomised, Controlled, Multi-centre Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus SoC Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive, Resectable, Stages II and IIIA Non-small Cell Lung Cancer (NeoADAURA) $44,695 2 payments
A Phase 3, External Placebo Controlled, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD) $40,450 1 payment
A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination with Standard of Care Chemotherapy and Durvalumab with Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care $38,494 6 payments
AZD2693, Cardiovascular, Renal and Metabolism $38,400 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.